Compare Asuransi Jiwa Syariah Jasa Mitra Abadi Tbk. (JMAS) vs Organon Pharma Indonesia Tbk. (SCPI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Asuransi Jiwa Syariah Jasa Mitra Abadi Tbk. vs Organon Pharma Indonesia Tbk. — how do they compare? Asuransi Jiwa Syariah Jasa Mitra Abadi Tbk. trades at Rp228 (market cap 228B), while Organon Pharma Indonesia Tbk. trades at Rp29,000 (market cap 104.4B). The key difference: Asuransi Jiwa Syariah Jasa Mitra Abadi Tbk. is far larger — about 2.2× Organon Pharma Indonesia Tbk.'s market cap. Which is the better fit depends on your goals.
| JMAS | SCPI | |
|---|---|---|
Market Cap | 228B | 104.4B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Asuransi Jiwa Syariah Jasa Mitra Abadi Tbk.
PT Asuransi Jiwa Syariah Jasa Mitra Abadi Tbk (the Company) was established under the laws and regulations of the law Republic of Indonesia originally under the name "PT Jasa Mitra Abadi", domiciled in South Jakarta based on Notarial Deed No. 22 dated August 15, 2014, by Rosida Rajagukguk Siregar, Bachelor of Law, Master of Notary, Notary in South Jakarta.
Read more on JMAS →About Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Read more on SCPI →
